Brazilian Landscape of Hepatocellular Carcinoma

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
Citação
JCO GLOBAL ONCOLOGY, v.9, article ID e2200416, 10p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The incidence of hepatocellular carcinoma (HCC) is expected to increase in the coming years, and strategies to mitigate the burden of this disease are needed in different regions. Geographic variations in epidemiology and risk factors, such as viral hepatitis and metabolic disease, pose challenges in adopting programs for early detection programs and management of patients with HCC. Brazil, like other countries, has high economic and social inequality, with heterogeneous access to health care. Viral hepatitis is themain risk factor but there is growing awareness of fatty liver disease. Risk factor monitoring and screening programs are unmet priorities because patients are often diagnosed at later stages. Advances in the management of patients with HCC have been made in recent years, including new tools for selecting patients for liver transplantation, sophisticated surgical techniques, and new systemic agents. High-volume academic centers often achieve favorable results through the adoption and application of established treatments, but this is not a reality in most regions of Brazil, because of disparities in wealth and resources. As HCC management requires a coordinated and multidisciplinary team, the role of local referral centers in decentralizing access to treatments and promoting health education in different regions should be encouraged and supported.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/58882
Referências
  1. Abdelaziz A, 2014, SURG ENDOSC, V28, P3429, DOI 10.1007/s00464-014-3617-4
  2. Abou-Alfa Ghassan K, 2022, NEJM Evid, V1, pEVIDoa2100070, DOI 10.1056/EVIDoa2100070
  3. Adam R, 2012, J HEPATOL, V57, P675, DOI 10.1016/j.jhep.2012.04.015
  4. Andolino DL, 2011, INT J RADIAT ONCOL, V81, pE447, DOI 10.1016/j.ijrobp.2011.04.011
  5. [Anonymous], 2021, Relat orio de gestao INCA 2020/Instituto Nacional de Cancer^ Jose Alencar Gomes da Silva
  6. Balbi E, 2022, MEDICINE, V101, DOI 10.1097/MD.0000000000030614
  7. Baten J., 2016, A history of the global economy: 1500 to the present
  8. Benedict SH, 2010, MED PHYS, V37, P4078, DOI 10.1118/1.3438081
  9. Bittencourt PL, 2016, LIVER TRANSPLANT, V22, P1254, DOI 10.1002/lt.24487
  10. Brazilian Society of Radiotherapy, Radiotherapy development plan for the next decade
  11. Bruix J, 2019, NAT REV GASTRO HEPAT, V16, P617, DOI 10.1038/s41575-019-0179-x
  12. Brunello F, 2008, SCAND J GASTROENTERO, V43, P727, DOI 10.1080/00365520701885481
  13. Carrilho FJ, 2010, CLINICS, V65, P1285, DOI 10.1590/S1807-59322010001200010
  14. Chagas AL, 2019, EUR J GASTROEN HEPAT, V31, P1148, DOI 10.1097/MEG.0000000000001448
  15. Chen MS, 2006, ANN SURG, V243, P321, DOI 10.1097/01.sla.0000201480.65519.b8
  16. Cheng AL, 2022, J HEPATOL, V76, P862, DOI [10.1016/j.jhep.2021.11.030, 10.1016/j.jceh.2022.07.003]
  17. Chen ATC, 2021, REP PRACT ONCOL RADI, V26, P226, DOI 10.5603/RPOR.a2021.0035
  18. Comissao Nacional de Incorporacao de Tecnologias no SUS, Sorafenibe para carcinoma hepatocelular (CHC) irressecavel ou avancado
  19. Comito T, 2022, CURR ONCOL, V29, P8802, DOI 10.3390/curroncol29110692
  20. Cotrim HP, 2016, CLINICS, V71, P281, DOI 10.6061/clinics/2016(05)07
  21. Cucchetti A, 2013, J HEPATOL, V59, P300, DOI 10.1016/j.jhep.2013.04.009
  22. da Fonseca LG, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-5173-0
  23. Soares LSD, 2020, EPIDEMIOL SERV SAUDE, V29, DOI [10.5123/s1679-49742020000100014, 10.5123/S1679-49742020000100014]
  24. De Villa V, 2007, ONCOLOGIST, V12, P1321, DOI 10.1634/theoncologist.12-11-1321
  25. El-Khoueiry AB, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.4078
  26. El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2
  27. European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
  28. Fang Y, 2014, J GASTROEN HEPATOL, V29, P193, DOI 10.1111/jgh.12441
  29. Feng K, 2012, J HEPATOL, V57, P794, DOI 10.1016/j.jhep.2012.05.007
  30. Fernandes GD, 2021, J GASTROINTEST CANC, V52, P952, DOI 10.1007/s12029-020-00508-7
  31. Finn RS, 2020, J CLIN ONCOL, V38, P2960, DOI 10.1200/JCO.20.00808
  32. Finn RS, 2020, J CLIN ONCOL, V38, P193, DOI 10.1200/JCO.19.01307
  33. Fonseca BD, 2022, LANCET REG HEALTH-AM, V7, DOI 10.1016/j.lana.2021.100153
  34. Fu CC, 2014, HEPATO-GASTROENTEROL, V61, P1722
  35. Gardini AC, 2018, ONCOTARGETS THER, V11, P6555, DOI 10.2147/OTT.S170836
  36. Germani G, 2010, J HEPATOL, V52, P380, DOI 10.1016/j.jhep.2009.12.004
  37. Giorgio A, 2011, ANTICANCER RES, V31, P2291
  38. Gómez EJ, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2851-1
  39. Goncalves Carlos S., 1997, Revista do Instituto de Medicina Tropical de Sao Paulo, V39, P165, DOI 10.1590/S0036-46651997000300008
  40. HERMAN Paulo, 2016, Arq. Gastroenterol., V53, P169, DOI 10.1590/S0004-28032016000300009
  41. Huang JW, 2010, ANN SURG, V252, P903, DOI 10.1097/SLA.0b013e3181efc656
  42. Ioannou GN, 2007, CLIN GASTROENTEROL H, V5, P938, DOI 10.1016/j.cgh.2007.02.039
  43. Izumi N, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.4002
  44. Jenne CN, 2013, NAT IMMUNOL, V14, P996, DOI 10.1038/ni.2691
  45. Kamal A, 2019, J GASTROINTEST ONCOL, V10, P562, DOI 10.21037/jgo.2019.01.34
  46. Kikuchi L, 2014, WORLD J GASTROENTERO, V20, P1585, DOI 10.3748/wjg.v20.i6.1585
  47. Kim TH, 2021, J HEPATOL, V74, P603, DOI 10.1016/j.jhep.2020.09.026
  48. Kokudo T, 2016, J HEPATOL, V65, P938, DOI 10.1016/j.jhep.2016.05.044
  49. Kudo M, 2021, J HEPATOL, V75, P600, DOI 10.1016/j.jhep.2021.04.047
  50. LAI CL, 1988, CANCER, V62, P479, DOI 10.1002/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L
  51. Lammer J, 2010, CARDIOVASC INTER RAD, V33, P41, DOI 10.1007/s00270-009-9711-7
  52. Lencioni RA, 2003, RADIOLOGY, V228, P235, DOI 10.1148/radiol.2281020718
  53. Lin SM, 2005, GUT, V54, P1151, DOI 10.1136/gut.2004.045203
  54. Lin SM, 2004, GASTROENTEROLOGY, V127, P1714, DOI 10.1053/j.gastro.2004.09.003
  55. Llovet JM, 2003, HEPATOLOGY, V37, P429, DOI 10.1053/jhep.2003.50047
  56. Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X
  57. Marcassa J, 2017, INT C ADV RAD ONCOLO
  58. Matas AJ, 2015, AM J TRANSPLANT, V15, DOI 10.1111/ajt.13195
  59. Luz JHM, 2017, CANCER IMAGING, V17, DOI 10.1186/s40644-017-0108-6
  60. Merchant N, 2011, INT J HEPATOL, V2011, DOI 10.4061/2011/142085
  61. Moraes FY, 2016, REV ASSOC MED BRAS, V62, P782, DOI 10.1590/1806-9282.62.08.782
  62. Munoz-Schuffenegger P, 2021, RADIOTHER ONCOL, V156, P120, DOI 10.1016/j.radonc.2020.11.033
  63. Ng KKC, 2017, BRIT J SURG, V104, P1775, DOI 10.1002/bjs.10677
  64. Ohri PN, 2021, INT J RADIAT ONCOL, V110, P188, DOI 10.1016/j.ijrobp.2017.12.288
  65. onlinelibrary, Epidemiology of hepatocellular carcinoma, DOI [10.1002/hep.31288, DOI 10.1002/HEP.31288]
  66. Pan YX, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01639
  67. Pasini F, 2020, Hepatoma Res, V26
  68. planalto, Constituicao da Republica Federativa do Brasil
  69. Ren ZG, 2021, LANCET ONCOL, V22, P977, DOI 10.1016/S1470-2045(21)00252-7
  70. Sapir E, 2018, INT J RADIAT ONCOL, V100, P122, DOI 10.1016/j.ijrobp.2017.09.001
  71. Shibata T, 2002, RADIOLOGY, V223, P331, DOI 10.1148/radiol.2232010775
  72. Shiina S, 2005, GASTROENTEROLOGY, V129, P122, DOI 10.1053/j.gastro.2005.04.009
  73. Signorelli IV, 2016, CLINICS, V71, P361, DOI 10.6061/clinics/2016(07)01
  74. da Silva MJS, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6190-3
  75. Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
  76. Violi NV, 2018, LANCET GASTROENTEROL, V3, P317, DOI 10.1016/S2468-1253(18)30029-3
  77. Wahl DR, 2016, J CLIN ONCOL, V34, P452, DOI 10.1200/JCO.2015.61.4925
  78. Wei XB, 2019, J CLIN ONCOL, V37, P2141, DOI 10.1200/JCO.18.02184
  79. Yau T, 2019, ANN ONCOL, V30, P874
  80. Yau T, 2020, JAMA ONCOL, V6, DOI 10.1001/jamaoncol.2020.4564
  81. Yeo W, 2005, JNCI-J NATL CANCER I, V97, P1532, DOI 10.1093/jnci/dji315
  82. Yin L, 2014, J HEPATOL, V61, P82, DOI 10.1016/j.jhep.2014.03.012
  83. Yoon SM, 2018, JAMA ONCOL, V4, P661, DOI 10.1001/jamaoncol.2017.5847
  84. Yu J, 2017, GUT, V66, P1172, DOI 10.1136/gutjnl-2016-312629
  85. Zhu AX, 2018, LANCET ONCOL, V19, P940, DOI 10.1016/S1470-2045(18)30351-6

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT